AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for LIM homeobox transcription factor 1-alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8TE12

UPID:

LMX1A_HUMAN

Alternative names:

LIM/homeobox protein 1.1; LIM/homeobox protein LMX1A

Alternative UPACC:

Q8TE12; B3KXP6; Q0VDB5; Q5VWG4; Q8TE11

Background:

LIM homeobox transcription factor 1-alpha, also known as LMX1A, plays a pivotal role in the development of the central nervous system and vertebrae. It functions as a transcriptional activator, crucial for the development of the roof plate and specification of dorsal cell fates. Its activity involves binding to the FLAT element in the insulin gene promoter, highlighting its significance in gene expression regulation.

Therapeutic significance:

LMX1A is linked to Deafness, autosomal dominant, 7 (DFNA7), a form of non-syndromic sensorineural hearing loss. This condition underscores the protein's clinical relevance, as it presents a target for therapeutic intervention. Understanding the role of LIM homeobox transcription factor 1-alpha could open doors to potential therapeutic strategies for sensorineural deafness.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.